JP2013543481A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013543481A5 JP2013543481A5 JP2013517506A JP2013517506A JP2013543481A5 JP 2013543481 A5 JP2013543481 A5 JP 2013543481A5 JP 2013517506 A JP2013517506 A JP 2013517506A JP 2013517506 A JP2013517506 A JP 2013517506A JP 2013543481 A5 JP2013543481 A5 JP 2013543481A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- surfactant
- preparation
- agent
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 33
- 239000013078 crystal Substances 0.000 claims 24
- 239000000243 solution Substances 0.000 claims 19
- 238000004519 manufacturing process Methods 0.000 claims 16
- 239000004094 surface-active agent Substances 0.000 claims 16
- 239000000725 suspension Substances 0.000 claims 14
- -1 1,2-benzisothiazol-3-yl Chemical group 0.000 claims 12
- 239000007864 aqueous solution Substances 0.000 claims 12
- 239000003405 delayed action preparation Substances 0.000 claims 12
- 238000002360 preparation method Methods 0.000 claims 12
- 239000004480 active ingredient Substances 0.000 claims 11
- 238000002425 crystallisation Methods 0.000 claims 11
- 230000008025 crystallization Effects 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- 239000003960 organic solvent Substances 0.000 claims 9
- 239000007924 injection Substances 0.000 claims 8
- 238000002347 injection Methods 0.000 claims 8
- 239000006172 buffering agent Substances 0.000 claims 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 6
- HUXSAESWQBPYHL-UHFFFAOYSA-N azecane-2,10-dione Chemical compound O=C1CCCCCCCC(=O)N1 HUXSAESWQBPYHL-UHFFFAOYSA-N 0.000 claims 6
- 239000000872 buffer Substances 0.000 claims 6
- 239000004359 castor oil Substances 0.000 claims 6
- 235000019438 castor oil Nutrition 0.000 claims 6
- 238000001914 filtration Methods 0.000 claims 6
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 6
- 239000007951 isotonicity adjuster Substances 0.000 claims 6
- 239000012046 mixed solvent Substances 0.000 claims 6
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 239000008215 water for injection Substances 0.000 claims 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims 4
- 239000002253 acid Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003981 vehicle Substances 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 2
- 229920001213 Polysorbate 20 Polymers 0.000 claims 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims 2
- 238000011049 filling Methods 0.000 claims 2
- 239000007788 liquid Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 229960003194 meglumine Drugs 0.000 claims 2
- 238000002156 mixing Methods 0.000 claims 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 2
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 2
- 229920001993 poloxamer 188 Polymers 0.000 claims 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 2
- 229940068977 polysorbate 20 Drugs 0.000 claims 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims 2
- 239000012929 tonicity agent Substances 0.000 claims 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 229960003121 arginine Drugs 0.000 claims 1
- 229960000686 benzalkonium chloride Drugs 0.000 claims 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 229940001593 sodium carbonate Drugs 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
- 239000001488 sodium phosphate Substances 0.000 claims 1
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 1
- 235000011008 sodium phosphates Nutrition 0.000 claims 1
- 239000008174 sterile solution Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 1
- 229960000281 trometamol Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39406910P | 2010-10-18 | 2010-10-18 | |
| US61/394,069 | 2010-10-18 | ||
| PCT/JP2011/074375 WO2012053654A1 (en) | 2010-10-18 | 2011-10-18 | Sustained-release formulation for injection |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016033019A Division JP6173502B2 (ja) | 2010-10-18 | 2016-02-24 | 注射用徐放性製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013543481A JP2013543481A (ja) | 2013-12-05 |
| JP2013543481A5 true JP2013543481A5 (enExample) | 2014-12-04 |
| JP5893616B2 JP5893616B2 (ja) | 2016-03-23 |
Family
ID=45933169
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013517506A Expired - Fee Related JP5893616B2 (ja) | 2010-10-18 | 2011-10-18 | 注射用徐放性製剤 |
| JP2016033019A Expired - Fee Related JP6173502B2 (ja) | 2010-10-18 | 2016-02-24 | 注射用徐放性製剤 |
| JP2017131059A Expired - Fee Related JP6410889B2 (ja) | 2010-10-18 | 2017-07-04 | 注射用徐放性製剤 |
| JP2018179030A Pending JP2019006822A (ja) | 2010-10-18 | 2018-09-25 | 注射用徐放性製剤 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016033019A Expired - Fee Related JP6173502B2 (ja) | 2010-10-18 | 2016-02-24 | 注射用徐放性製剤 |
| JP2017131059A Expired - Fee Related JP6410889B2 (ja) | 2010-10-18 | 2017-07-04 | 注射用徐放性製剤 |
| JP2018179030A Pending JP2019006822A (ja) | 2010-10-18 | 2018-09-25 | 注射用徐放性製剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9469630B2 (enExample) |
| EP (1) | EP2629775A4 (enExample) |
| JP (4) | JP5893616B2 (enExample) |
| KR (1) | KR101936968B1 (enExample) |
| CN (3) | CN107595771A (enExample) |
| CA (1) | CA2814840C (enExample) |
| WO (1) | WO2012053654A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| AR090775A1 (es) * | 2012-04-23 | 2014-12-03 | Otsuka Pharma Co Ltd | Preparado inyectable |
| WO2014084921A1 (en) * | 2012-11-27 | 2014-06-05 | Rose Stuart | Pharmaceutical manufacturing method and compositions |
| JP2016513699A (ja) * | 2013-03-15 | 2016-05-16 | エピザイム，インコーポレイティド | 癌の治療のための注射製剤 |
| TW201609145A (zh) * | 2013-12-25 | 2016-03-16 | 參天製藥股份有限公司 | 注射劑及形成緩釋（ｄｅｐｏｔ）之方法 |
| CA2960287A1 (en) * | 2014-09-17 | 2016-03-24 | Epizyme, Inc. | Injectable formulations for treating cancer |
| KR101792414B1 (ko) * | 2016-05-19 | 2017-11-01 | 삼성전기주식회사 | 박막 커패시터 및 그 제조방법 |
| CN105963253A (zh) * | 2016-06-19 | 2016-09-28 | 朱武欣 | 一种罗替戈汀长效水性混悬型注射剂 |
| WO2018015915A1 (en) | 2016-07-22 | 2018-01-25 | Cadila Healthcare Limited | A parenteral controlled release composition of an atypical antipsychotic agent |
| WO2018043613A1 (ja) * | 2016-08-31 | 2018-03-08 | 大日本住友製薬株式会社 | 水性懸濁型製剤 |
| US10252229B2 (en) * | 2017-06-30 | 2019-04-09 | Snowie LLC | System comprising a pump attached to a tank casing for mixing a fluid |
| JPWO2019167977A1 (ja) * | 2018-02-28 | 2021-02-04 | 大日本住友製薬株式会社 | 水性懸濁型医薬製剤 |
| SG11202008233WA (en) * | 2018-02-28 | 2020-09-29 | Sumitomo Dainippon Pharma Co Ltd | Aqueous suspension pharmaceutical preparation with controlled dissolution |
| JP7214103B2 (ja) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | 遊技機 |
| JP7214100B2 (ja) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | 遊技機 |
| JP7214102B2 (ja) * | 2019-01-18 | 2023-01-30 | 株式会社大一商会 | 遊技機 |
| TW202100157A (zh) * | 2019-03-07 | 2021-01-01 | 日商大日本住友製藥股份有限公司 | 經控制粒子徑之水性懸濁型醫藥製劑 |
| CN110478131B (zh) * | 2019-08-05 | 2022-01-11 | 思必康（厦门）新材料有限公司 | 一种pH响应变色的纱布及其制备方法和该纱布的应用 |
| US11041740B1 (en) | 2019-12-20 | 2021-06-22 | EmpNia Inc. | Method and apparatus for real time respiratory gating signal generation and detection of body deformation using embedded fiber Bragg gratings |
| CN119431400A (zh) * | 2020-03-27 | 2025-02-14 | 波士顿科学国际有限公司 | 用于使药物结晶的方法 |
| EP4196106A1 (en) * | 2020-08-11 | 2023-06-21 | Auxilla Pharmaceuticals and Research LLP | A non-aqueous suspension of anticancer agent |
| JP2024507528A (ja) | 2021-02-24 | 2024-02-20 | オークウッド ラボラトリーズ，エル．エル．シー． | ルラシドンを含むミクロスフェア製剤ならびにその製造方法および使用方法 |
| US20240124437A1 (en) | 2021-03-31 | 2024-04-18 | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Injectable lurasidone suspension and preparation method therefor |
| CN120078778A (zh) * | 2024-09-25 | 2025-06-03 | 山东百诺医药股份有限公司 | 一种伏硫西汀酯药物组合物及其制备方法和用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| TW491847B (en) * | 1996-05-07 | 2002-06-21 | Pfizer | Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| US6617321B2 (en) | 1997-09-30 | 2003-09-09 | Eli Lilly And Company | 2-methyl-thieno-benzodiazepine formulation |
| CA2304568C (en) | 1997-09-30 | 2008-08-12 | Eli Lilly And Company | Olanzapine pamoate formulations |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| FI105074B (fi) | 1997-12-31 | 2000-06-15 | Leiras Oy | Farmaseuttisen formulaation valmistusmenetelmä |
| DE69917663T2 (de) | 1998-09-30 | 2005-05-25 | Eli Lilly And Co., Indianapolis | 2-methyl-thieno-benzodiazepin-formulierung |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| US20040022862A1 (en) | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
| WO2002078673A1 (fr) | 2001-03-29 | 2002-10-10 | Takeda Chemical Industries, Ltd. | Procede de production d'un medicament sous forme de granules fins |
| JP4175800B2 (ja) * | 2001-11-27 | 2008-11-05 | 住友化学株式会社 | イミド誘導体の製造方法 |
| DE10218110A1 (de) | 2002-04-23 | 2003-11-20 | Jenapharm Gmbh | Verfahren zum Herstellen von Kristallen von Arzneimittelhilfsstoffen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen |
| GB0216416D0 (en) * | 2002-07-15 | 2002-08-21 | Novartis Ag | Organic compounds |
| JP4610485B2 (ja) | 2003-07-29 | 2011-01-12 | 大日本住友製薬株式会社 | イミド化合物の製造方法 |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| TWI371274B (en) | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| BRPI0415531B8 (pt) | 2003-10-23 | 2021-05-25 | Otsuka Pharma Co Ltd | formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação |
| AU2005307797B2 (en) | 2004-11-16 | 2011-06-02 | Alkermes Pharma Ireland Limited | Injectable nanoparticulate olanzapine formulations |
| EP1838716B1 (en) | 2005-01-05 | 2011-06-01 | Eli Lilly And Company | Olanzapine pamoate dihydrate |
| JP2008538751A (ja) | 2005-04-13 | 2008-11-06 | ファイザー・プロダクツ・インク | ナノ粒子組成物を持続放出するための注射用デポ製剤および方法 |
| DK1884242T3 (da) | 2005-05-26 | 2013-05-06 | Dainippon Sumitomo Pharma Co | Farmaceutisk sammensætning omfattende lurasidon |
| WO2006134864A1 (ja) * | 2005-06-13 | 2006-12-21 | Dainippon Sumitomo Pharma Co., Ltd. | 可溶化型製剤 |
| CA2622758A1 (en) | 2005-09-15 | 2007-03-29 | Elan Pharma International, Limited | Nanoparticulate aripiprazole formulations |
| US20090087492A1 (en) | 2006-03-14 | 2009-04-02 | Merck & Co., Inc. | Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use |
| US20100266696A1 (en) | 2007-12-13 | 2010-10-21 | Gerhard Muhrer | Organic Compounds |
-
2011
- 2011-10-18 CN CN201710826880.1A patent/CN107595771A/zh active Pending
- 2011-10-18 CN CN201180060225.0A patent/CN103249416B/zh not_active Expired - Fee Related
- 2011-10-18 CA CA2814840A patent/CA2814840C/en not_active Expired - Fee Related
- 2011-10-18 EP EP11834492.8A patent/EP2629775A4/en not_active Withdrawn
- 2011-10-18 WO PCT/JP2011/074375 patent/WO2012053654A1/en not_active Ceased
- 2011-10-18 KR KR1020137011618A patent/KR101936968B1/ko not_active Expired - Fee Related
- 2011-10-18 CN CN201710826877.XA patent/CN107625728A/zh active Pending
- 2011-10-18 US US13/276,039 patent/US9469630B2/en not_active Expired - Fee Related
- 2011-10-18 JP JP2013517506A patent/JP5893616B2/ja not_active Expired - Fee Related
-
2016
- 2016-02-12 US US15/043,235 patent/US20160158228A1/en not_active Abandoned
- 2016-02-24 JP JP2016033019A patent/JP6173502B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-04 JP JP2017131059A patent/JP6410889B2/ja not_active Expired - Fee Related
-
2018
- 2018-09-12 US US16/128,597 patent/US20190010149A1/en not_active Abandoned
- 2018-09-25 JP JP2018179030A patent/JP2019006822A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9469630B2 (en) | Sustained-release formulation for injection | |
| JP6306609B2 (ja) | 医薬組成物 | |
| KR101053780B1 (ko) | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 | |
| JP2019167377A (ja) | 後眼部へ薬物を送達するための眼用製剤 | |
| CN101322682A (zh) | 难溶性药物纳米粒的制备方法 | |
| JP6225113B2 (ja) | 固体粒子の製造方法 | |
| JP2003535893A5 (enExample) | ||
| CN104010661A (zh) | 含有二丁基羟基甲苯的制剂及二丁基羟基甲苯的稳定化方法 | |
| JP6081173B2 (ja) | 眼科用水性組成物 | |
| CN102091028A (zh) | 一种依达拉奉注射液及其制备方法 | |
| US20220409588A1 (en) | Oral formulations of edaravone and method of manufacturing thereof | |
| US20200261383A1 (en) | Pharmaceutical compositions | |
| HUE027923T2 (en) | Pharmaceutical Nanosuspension | |
| AU2017318591A1 (en) | Bendamustine solution formulations | |
| CZ287115B6 (en) | Agent for ultrasonic diagnostics, ultrasonic contrast medium, set for preparing such contrast medium and process for preparing said agent | |
| CN104586764A (zh) | 一种棕榈酸帕利培酮肌内注射用混悬剂及其制备方法 | |
| CN102266549A (zh) | 一种含有阿加曲班的注射用制剂 | |
| CN102100668B (zh) | 高级脂肪酸衍生物微乳及其制备方法和应用 | |
| JP2007016024A (ja) | ロフルミラスト点眼液 | |
| RU2192855C1 (ru) | Способ получения лекарственного средства для инъекций на основе амиодарона | |
| WO2003099288A1 (en) | Medicinal composition | |
| CN105330669A (zh) | 2-氨基-7-异丙基-5-氧代-5H-[1]苯并吡喃并[2,3-b]吡啶-3-甲酸的多晶型物及其制备和应用 | |
| US20230310417A1 (en) | Injectable aripiprazole formulation | |
| CN102204890A (zh) | 复水性能优良的依替巴肽冻干粉针 | |
| CN108969476A (zh) | 一种含长春西汀的注射用药组合物及其制备方法 |